Thesis
EKTERLY's first-cycle commercial traction and multi-jurisdictional approvals validated the oral on-demand HAE thesis, culminating in Chiesi's $1.9B acquisition at $27/share
EKTERLY (sebetralstat), a plasma kallikrein inhibitor, received US, EU, and Japan approvals for acute HAE attacks in adults and adolescents, establishing it as the first oral on-demand therapy in the class. The thesis resolved affirmatively: $49M in first-year US revenue, ~20% patient penetration, and a completed $1.9B acquisition by Chiesi Farmaceutici closed June 11, 2026. KalVista no longer trades as an independent public company; the investment thesis has been fully realized at $27.00 per share.
Focus
Chiesi acquisition of KalVista completed at $27/share, stock delisted from Nasdaq
2026-06-11
Bull
Shareholders who tendered received the full $27.00 per share in cash, representing a clean exit at the acquisition price. The strong EKTERLY commercial traction — $49M in its first months post-launch and ~20% US patient penetration — validated the $1.9B equity consideration paid by Chiesi. Any remaining shareholders in a back-end merger squeeze-out should receive the same $27.00 per share.
Bear
Shareholders who did not tender prior to the June 11, 2026 deadline may face procedural delays in receiving consideration through a subsequent short-form merger process. There is no longer any equity upside optionality, as the deal is closed at a fixed cash price with no contingent value rights tied to EKTERLY milestones such as pediatric NDA approval or international expansion.
Unlock the full thesis for KALV.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.